75a50322Q00011 Probenecid

The Division of Strategic National Stockpile (DSNS) has a need for Probenecid Oral Tablets 500mg, 8 tablets per bottle. (National Drug Code 71626-999-08 or equivalent) . (See attachment for details). COMBINED SYNOPSIS SOLICITATION The Division of Strategic National Stockpile (DSNS) has a need for Probenecid Oral Tablets 500mg, 8 tablets per bottle. (National Drug Code 71626-999-08 or equivalent) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; quotes are being requested. The solicitation number is 75A50322Q00011 and is hereby issued as a Request for Quote (RFQ) using the Simplified Acquisition Procedures for FAR 13 and FAR Part 12. The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2022-06. This acquisition is being posted as a full and open requirement. The associated North American Industrial Classification System (NAICS) code for this procurement is 325412- Pharmaceutical Preparation Manufacturing size standards in number of employees 1,250. Office of the Assistant Secretary for Preparedness and Response (ASPR), Division of Strategic National Stockpile (DSNS) intends to award a firm-fixed-price contract. The Government intends to evaluate offers and award a contract without discussions. However, the Government may, at its sole discretion, elect to conduct discussions if determined to be in the best interest of the Government. The period of performance is anticipated to total 60 months after award. The provision at FAR 52.212-1, Instructions to Offerors-Commercial Products and Commercial Services, applies to this acquisition. The provision 52.212-2, Evaluation-Commercial Products and Commercial Services, applies to this procurement. Addenda to the provision include evaluation factors and evaluation criteria. Offerors shall include a completed copy of FAR 52.212-3, Offeror Representations and Certifications-Commercial Products and Commercial Services, with its offer. (Note, if offerors are registered within the System for Award Management (SAM) and certs and reps are up to date, make a statement to that effect in accordance with this clause). The clause at 52.212-4, Contract Terms and Conditions-Commercial Products and Commercial Services, applies to this acquisition. The clause at 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders Commercial Products and Commercial Services, applies to this acquisition and FAR clauses applicable include 52.219-9, 52.219-16, 52.222-3, 52.222-19, 52.222-21, 52.222-26, 52.222-35, 52.222-36, 52.222-37, 52.222-40, 52.225-13, and 52.232-33. Other applicable clauses include Health & Human Services Acquisition Regulation (HHSAR) clauses below. All questions regarding this RFQ of contractual or technical nature, must be submitted electronically by email to OSContracting@cdc.gov no later than 2:00 PM, ET, August 3, 2022. For proper submission of questions, include the solicitation number and the word - QUESTION in the subject of the email. The Government's responses to questions will be posted as an amendment to the combined synopsis/solicitation posting. Please be advised that the Government reserves the right to transmit those questions and answers of a common interest to all prospective offerors. The point of contact for information regarding this combined synopsis/solicitation is Kimberly Golden, Contracting Officer Office of Resource Management (ORM) Assistant Secretary for Preparedness and Response (ASPR) U.S. Department of Health and Human Services (HHS) Email: OSContracting@cdc.gov Quotes are due no later than August 11, 2022 on or before 2:00 PM Eastern Time The Subject Line RFQ Probenecid Oral Tablets by email to OSContracting@cdc.gov .